Aaron Rodgers’s Vax Claims Supported by New Data from Regeneron

Share this story:

Regeneron — a Big Pharma Corporation — may have produced a drug that not only helps treat COVID, but also helps one avoid catching it, the Daily Caller reported.

Notably, Green Bay Packers quarterback Aaron Rodgers promoted Regeneron as an alternative treatment for COVID in place of the vaccine.

Nonetheless, the mainstream media angrily assaulted him for his apparently subversive claim that a Big Pharma product other than vaccines might also slow the spread of the virus.

In a press release, the company claimed that its consumer product reduced the risk of contracting COVID-19 by 81.6%. Further, zero of the trial patients had to be hospitalized, even if they did contract COVID.

Previously, such treatments — called monoclonal antibodies — have been limited in use to the treatment of patients who have already contracted COVID-19. But it now appears that the drug may work as a preventative measure as well. The protection works for up to eight months after treatment, according to the report.

Rodgers said that he also used ivermectin and hydroxychloroquine since contracting the deadly virus.

Of course, these two drugs have been under fire for months now, especially because of their association with former President Donald Trump.

Rodgers has joined a group of disaffected liberals, like Joe Rogan, who think that the vaccine and vaccine mandates are a step too far for Americans. Part of their resistance has included strong push back against the mainstream media.

Rogan, for example, forced CNN’s chief medical correspondent, Sanjay Gupta, to admit that the network falsely claimed Rogan took “horse dewormer” as a COVID-19 treatment.

Merck, a major producer of ivermectin, announced in October that, despite its hand in the production of ivermectin, it would join the FDA in the attack on the long-used drug

“We do not believe that the data available support the safety and efficacy of ivermectin,” a company statement said, “beyond the doses and populations indicated in the regulatory agency-approved prescribing information.”

Leave a Reply